If I recall from slides a few months ago , Cytodyn was going to attack the most complicated piece of the BLA first , then submit the remaining pieces once the fda provided feedback to them . We know it’s a rolling review which is a plus so hoping we are within a reasonable range of final review based on what Cytodyn managment mentioned a few months ago